# Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Canonical URL: https://biopharmsignal.com/news/PCRX/pacira-biosciences-sends-letter-to-stockholders-reiterating-superior-qualifications-of-its-board-nominees
Ticker: PCRX
Company: Pacira BioSciences
Source: Pacira BioSciences
Published: 2026-05-12 20:01 EST
Original Source URL: https://investor.pacira.com
## Summary

Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.

## Article Body
Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.
## Recent Company News
- 2026-06-01 20:50 EST — [Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees](https://biopharmsignal.com/news/PCRX/pacira-biosciences-highlights-leading-independent-proxy-advisory-firm-iss-recommendation-to-vote-for-all-of-pacira-s-director-nominees) — Source: Pacira BioSciences
- 2026-05-28 20:20 EST — [Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees](https://biopharmsignal.com/news/PCRX/leading-independent-proxy-advisory-firm-glass-lewis-recommends-stockholders-vote-for-all-of-pacira-s-director-nominees) — Source: Pacira BioSciences
- 2026-05-27 20:20 EST — [Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees](https://biopharmsignal.com/news/PCRX/pacira-biosciences-mails-letter-to-stockholders-reiterating-confidence-in-the-company-s-strategic-direction-and-highly-qualified-nominees) — Source: Pacira BioSciences
- 2026-05-27 12:00 EST — [Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty](https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-real-world-study-showing-exparelr-use-was-associated-with-reduced-opioid-use-and-healthcare-costs-in-patients-undergoing-total-shoulder-arthroplasty) — Source: Pacira BioSciences
- 2026-05-26 12:00 EST — [Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy](https://biopharmsignal.com/news/PCRX/pacira-biosciences-sets-the-record-straight-regarding-doma-s-misleading-statements-about-pacira-s-intellectual-property-strategy) — Source: Pacira BioSciences
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)